Type 1 Diabetes – Current Treatment – Treatment Algorithms: Claims Data Analysis – Type 1 Diabetes (US)
Intensive insulin regimens have proven effective in delaying the progression of complications associated with untreated or poorly treated type 1 diabetes (T1D). Thus, insulin remains the cornerstone of the T1D market, and long-acting and rapid-acting insulins lead the patient share in the United States. The selection of branded insulin, the choice of regimen, and the order in which brands and/or regimens are used vary. In addition, the introduction of biosimilar / interchangeable insulins has added complexity to the T1D treatment algorithm, as has the growing adoption of insulin pumps.
Questions answered
- What patient shares do key therapies garner by line of therapy in newly diagnosed T1D patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed T1D patients?
- How have ultra-rapid-acting insulins (insulin aspart and insulin lispro-aabc) been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of T1D patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of T1D patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States.
Key drugs: Lyumjev, Lantus, Levemir, Toujeo, Apidra, NovoLog, Fiasp, Humalog, Admelog, Basaglar.
Key analyses
Brand / therapy usage across longitudinal patient sample
Newly diagnosed patient analysis
Treatment initiation and progression
Line of therapy analysis
Combination therapy analysis
Source of business for recently treated patients
Persistency and compliance analysis
Product-level patient flow charts
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Key feature
Dashboard featuring interactive visuals, easy navigation, and expanded analyses
